Healthcare Business Review: Warner Chilcott Gives Up On A SUITOR, Teva Begins Phase III TRIAL

Warner Chilcott Limited (NASDAQ:WCRX) announced on Tuesday that it has given up on finding a buyer, which is now four months after saying that it was pondering a sale. The news came as the firm announced a special dividend of $4 per share, and also reported that it would renew a $250 million repurchase program.

Don’t Miss: Arena Pharma Quarterly Earnings Approaching.

Bristol-Myers Squibb Company (NYSE:BMY) will now finalize its $7 billion purchase of Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) following its gaining tenders for 85.55 percent of the latter’s shares. Through the terms, AztraZenica Group plc (NYSE:AZN) will now pay $3.4 billion to the buyer, as part of a collaboration arrangement for developing and commercializing Amylin’s products.

Teva Pharmaceuticals Industries Limited (NASDAQ:TEVA) along with Active Biotech are ready to commence the third Phase III trial of their oral Laquinimod treatment for relapsing remitting multiple sclerosis. Two previous trials have brought positive results. In addition, Teva nominates former Bank Leumi Chief Executive Galia Maor as a director.

Don’t Miss: Seattle Genetics Earnings: Loss Narrows but Misses Estimates.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.